EGF and neoplasm: Remarkably, bi‐EGF‐IT increased the median survival time of tumor‐bearing animals from 14 days (DT390‐negative control group) to at least 60 days (P < 0.0001) (all mice in the bi‐EGF‐IT and erlotinib groups were euthanized at day 60 requested by the IACUC due to over the limits of end points in our animal protocol).